


J.P.Morgan

Q1 2026 Biopharma Licensing and Venture Report

April 2026

Fueled by

DEALFORMA 



Executive summary

Biopharma capital markets opened 2026 with selective momentum as licensing and M&A remained strong to lead venture and IPO activity

Biopharma financing and transaction activity in Q1 2026 continued to reflect a selective capital environment, with investors and acquirers concentrating around later-stage assets, differentiated science and programs with clearer clinical and commercial pathways. Venture fundraising remained uneven, reinforcing the importance of licensing, structured partnerships and M&A as primary sources of capital and strategic execution.

Large-cap biopharma remained active in pursuing external innovation through licensing and acquisitions. Deal structures remained milestone-heavy, while upfront economics stayed strong for the most competitive assets.

Here are a few highlights from our Q1 2026 report:

- **Venture investment in therapeutics and discovery platforms:** Biopharma venture funding totaled \$6.9 billion in Q1 2026, below the \$8.6 billion raised in Q1 2025, with deal count also trending lower.
- **Biopharma licensing partnerships:** Biopharma licensing reached \$82.7 billion in announced value in Q1 2026, with upfront cash representing 6% of total deal value.
- **M&A:** Biopharma M&A totaled \$40.9 billion across 32 deals in Q1 2026, following a strong 2025.
- **IPOs:** 6 biopharma IPOs raised \$1.8 billion in Q1 2026 for a strong start to the year, already passing full-year 2025.

J.P. Morgan is committed to your success. Our relationships, our capital and our skilled team of bankers and specialists dedicated to the life sciences and healthcare sectors reflect our conviction in the pivotal contributions these clients add to their stakeholders—society, shareholders and employees alike.

Our bankers' expertise ranges from advising companies at the earliest stage of formation to executing complex M&A and capital markets transactions. Regardless of the size or stage of your company, we are prepared, equipped and enthusiastic about helping you meet your strategic, financial and technical objectives.

Thank you for taking the time to read this report. We look forward to supporting you.

Kathryn McDonough
Head of Life Sciences
Innovation Economy, Commercial Banking
J.P. Morgan

Parameters

Biopharma companies are defined as firms developing therapeutics and technology platforms engaged in drug discovery, clinical R&D and commercialization.


Therapy areas, development stages, modalities and deal structures are segmented per the DealForma database.

Financials are based on disclosed figures curated by DealForma. Multiple tranches of the same Series are counted as one together.


Data as of March 31, 2026.

Biopharma venture investment increased exiting 2025 but remains below prior quarter highs

QUARTERLY BIOPHARMA VENTURE INVESTMENT VS. ANNUAL VENTURE DEAL COUNT¹



10-YEAR U.S. TREASURY YIELD VS. BIOPHARMA VENTURE DEPLOYMENT (INDEXED)^{1,2}




Biopharma venture funding in Q1 2026 came in at \$6.9 billion across 101 deals, a step down from the stronger pace seen in Q4 2025 but still indicative of a market with meaningful investor engagement. Biotech deal activity remained resilient despite broader geopolitical risks that emerged in the macroeconomy. The earlier momentum that built through 2025 appears to have moderated as investors weighed the reopened the exit landscape, both of which offer alternative liquidity paths that can temper the urgency of new venture commitments. Capital deployment remains focused on established portfolio companies with advanced pipelines and upcoming clinical catalysts, reflecting a market that continues to reward later-stage conviction over broad-based early-stage exploration.


Notes: ¹Financials based on disclosed figures. Data through March 31, 2026. ²Biopharma venture capital deployment is indexed to Q1 2020, where Q1 2020 = 100.

Licensing upfronts remain resilient as venture round count and breadth continue to narrow

COUNT OF VENTURE INVESTMENT ROUNDS BY ROUND SIZE¹



COUNT OF BIOPHARMA R&D LICENSES BY DISCLOSED UPFRONT CASH AMOUNT¹




Fewer companies completed venture financings in Q1 2026, and round activity remained below prior years across size bands. Capital continues to favor larger, later-stage financings over broad-based early-stage participation.

In contrast, licensing activity remains active, with 15 R&D licensing deals in Q1 2026 disclosing upfront payments above \$100 million. Large-cap biopharma continues to use licensing to secure differentiated assets amid a still-selective venture environment.

Note: ¹Financials based on disclosed figures. Data through March 31, 2026.

Early-stage venture funding remained under pressure as later-stage rounds continued to lead

BIOPHARMA SEED AND SERIES A VENTURE ACTIVITY VS. SERIES B+ VENTURE ACTIVITY¹



Seed and Series A funding totaled \$2.3 billion across 50 deals in Q1 2026, remaining well below Series B+ activity at \$4.5 billion across 51 deals. The early-stage recovery seen intermittently in 2024 and 2025 has not yet broadened. Despite later-stage public market activity picking up, first-time financings are on pace for their lowest annual count since pre-COVID.


Investors continue to prioritize later-stage companies with established data packages, de-risked development paths, and nearer-term catalysts, reinforcing the funding gap between early and late-stage issuers.

Notable Series A financings include Slate Medicine's \$130 million Series A and Poplar Therapeutics' \$95 million Series A.

Note: ¹Financials based on disclosed figures. Data through March 31, 2026.

Median round sizes remained strongest for Phase II and Phase III companies in Q1 2026

BIOPHARMA THERAPEUTICS AND PLATFORMS: MEDIAN VENTURE ROUND SIZE BY COMPANY STAGE AT FUNDING




Median venture round sizes in Q1 2026 reached \$40 million for platforms, \$39 million for preclinical, \$34 million for Phase I, \$73 million for Phase II, and \$108 million for Phase III companies, underscoring continued investor preference for more mature programs.

Financing levels remain highest for companies with validated mechanisms, clearer endpoints, and shorter paths to registration or commercialization, while earlier-stage issuers continue to face a more selective market.

Note: ¹Financials based on disclosed figures. Data through March 31, 2026.

U.S. biopharma hubs continued to lead global venture investment in Q1 2026

BIOPHARMA VENTURE INVESTMENT BY GEOGRAPHY, 2024 TO Q1 2026¹




From 2024 through Q1 2026, biopharma companies raised \$61.7 billion globally across 1,034 rounds, with \$44.1 billion – over 70% – flowing into U.S.-based companies.

The Bay Area (\$14.8B across 164 rounds) and Boston (\$12.5B across 166 rounds) continued to anchor the domestic landscape, together accounting for the lion's share of U.S. investment. San Diego (\$4.7B across 50 rounds) and Philadelphia (\$1.6B across 30 rounds) solidified their positions as the third and fourth largest U.S. hubs respectively, following two record-setting years that have elevated their profiles among investors seeking opportunities beyond the traditional coastal powerhouses.

Note: ¹Financials based on disclosed figures. Data through March 31, 2026.

European biopharma investment continued to increase

BIOPHARMA VENTURE INVESTMENT BY GEOGRAPHY, 2024 TO Q1 2026¹




European biopharma companies raised \$11.5 billion across 276 rounds from 2024 through Q1 2026, extending an upward trajectory that has been building steadily since 2022. The United Kingdom (\$4.3B across 89 rounds) and Switzerland (\$2.3B across 41 rounds) remained the leading hubs by capital raised. German biopharma companies have attracted increasing capital in recent periods, while France (\$696M across 30 rounds) continued to contribute meaningfully to the broader European ecosystem. The breadth and consistency of investment across multiple European markets suggests that the region is increasingly being viewed not just as a source of scientific talent, but as a viable and growing destination for venture capital seeking differentiated biopharma opportunities.

Note: ¹Financials based on disclosed figures. Data through March 31, 2026.

Licensing value stayed elevated in Q1 2026, supported by milestone-heavy structures

BIOPHARMA THERAPEUTICS AND PLATFORMS R&D LICENSING TOTALS AND UPFRONT CASH AS A PROPORTION OF DEAL VALUE¹




Biopharma licensing announced value reached \$82.7 billion in Q1 2026, following the record \$269.6 billion reached in 2025. While below 2025's pace, activity remains elevated relative to most prior years.

Upfront cash represented 6% of total deal value in Q1 2026, modestly below the 7% seen in 2023-25, highlighting the continued importance of large development, regulatory and commercial milestone packages in current deal structures.


Note: ¹Financials based on disclosed figures. Data through March 31, 2026.

Biologics continued to lead early-stage funding and licensing upfronts entering 2026

TOP BIOPHARMA MODALITIES: TOTAL SEED AND SERIES A VENTURE FUNDING¹



TOP BIOPHARMA MODALITIES: TOTAL LICENSING UPFRONT CASH AND EQUITY¹




Biologics remained the largest modality in both Seed/Series A venture funding and licensing upfront cash through 2025 and Q1 2026, reflecting sustained demand for differentiated antibody, protein and related platforms.

Small molecules continued to rank second across both venture and licensing, while gene therapy and genomics-related modalities also contributed meaningfully. Overall, capital remains concentrated in modalities with strong validation and multiple partnership pathways.

Note: ¹Financials based on disclosed figures. Data through March 31, 2026.

Big pharma continued to pay premium upfronts for late-stage assets in Q1 2026

IN-LICENSING BY BIG PHARMA: MEDIAN UPFRONT CASH & EQUITY AND NUMBER OF DEALS BY STAGE AT SIGNING¹



In Q1 2026, large-cap biopharma in-licensing remained focused on late-stage programs, with median upfront cash and equity of \$650 million for Phase II assets, though based on a limited number of deals. Phase III activity was more muted to start the year.


Big pharma also continued to transact selectively at earlier stages, including preclinical and platform deals, reflecting the need to balance near-term pipeline replacement with longer-term optionality.

Note: ¹Financials based on disclosed figures. Data through March 31, 2026. Stage of lead asset in multi-asset deals.


Oncology licensing economics remained strongest in Phase II and Phase III programs

IN-LICENSING BY BIG PHARMA: MEDIAN DEAL PAYMENTS AND NUMBER OF DEALS DISCLOSING VALUES BY STAGE AT SIGNING, ONCOLOGY ASSETS, 2024 TO Q1 2026¹


Median Upfront Cash & Equity Platform/Discovery > Phase III



Median Reg., Dev., Sales Milestones Platform/Discovery > Phase III



Median Total Deal Value Platform/Discovery > Phase III




Oncology remained the most active therapeutic area for large-cap biopharma licensing through Q1 2026, with the highest median upfronts and total deal values concentrated in Phase II and Phase III assets.

Later-stage oncology deals continue to command large milestone packages and premium upfront economics, reflecting sustained demand for differentiated assets with near-term commercial relevance.

Note: ¹Financials based on disclosed figures. Not all deals disclose all payment terms. Data through March 31, 2026. Stage of lead asset in multi-asset deals. Median reg., dev., sales milestones means regulatory, development, and sales milestones.

Biologics and small molecules continued to dominate licensing value in Q1 2026

R&D PARTNERSHIPS FOR TOP BIOPHARMA MODALITIES: TOTAL ANNOUNCED DEAL VALUE




In Q1 2026, announced R&D partnership value remained led by biologics, followed by small molecules, continuing the modality concentration seen throughout 2025.

Headline values continue to be supported by a relatively small number of large transactions, particularly in validated modalities and competitive target classes where strategic acquirers and partners are willing to pay a premium for differentiated assets. Other modalities—including gene therapy, cell therapy, gene editing, and immunotherapy—contribute more episodically, though their presence in the deal mix speaks to ongoing interest in next-generation platforms that could reshape the therapeutic landscape over time.


Note: ¹Financials based on disclosed figures. Data through March 31, 2026.

Obesity and diabetes licensing remained active in Q1 2026, though below 2025 peak levels

R&D PARTNERSHIPS FOR BIOPHARMA THERAPEUTICS AND DRUG DISCOVERY: OBESITY AND DIABETES



R&D PARTNERSHIPS FOR BIOPHARMA THERAPEUTICS AND DRUG DISCOVERY: GLP-1, GLP-1R AND GIP TARGETED THERAPEUTICS




R&D partnerships in obesity and diabetes reached \$22.0 billion in total announced deal value in Q1 2026, exceeding full-year 2025 levels, and upfront cash and equity was just as strong at \$1.3 billion through the first quarter.

For GLP-1, GLP-1R, and GIP-targeted therapeutics, last year's total deal value reached \$10.8 billion, following sporadic, but elevated, activity in 2023 and 2025. Q1 2026 has seen only two partnerships in for these targets, though financials were not disclosed for either. Strategic interest remains high, but deal flow is concentrated in a limited number of high-value transactions.


Note: ¹Financials based on disclosed figures. Data through March 31, 2026.

China-origin assets accounted for an even larger share of big pharma licensing in Q1 2026


GLOBAL LARGE-CAP BIOPHARMA IN-LICENSING FROM CHINESE BIOPHARMA: DEALS WITH AT LEAST \$50 MILLION PAID UP FRONT



SHARE OF GLOBAL BIG PHARMA DEALS WITH \$50M+ UPFRONT ORIGINATING FROM CHINA—DEAL COUNT



SHARE OF GLOBAL BIG PHARMA UPFRONTS OVER \$50M+ PAID TO CHINESE BIOPHARMA



Global large-cap biopharma continued to source assets from Chinese biopharma in Q1 2026, with seven deals carrying upfront payments of at least \$50 million and total upfront cash and equity of \$2.6 billion.


China-origin biopharma assets represented 50% of global large-cap pharma deals with upfronts above \$50 million in Q1 2026 and 75% of total upfront dollars in that group, highlighting China's growing role as a source of competitive licensing opportunities.

Early-stage biotechs are increasingly engaging Chinese Biopharma to evaluate if purchasing versus building early-stage assets is a more capital-efficient starting point.


Note: ¹Financials based on disclosed figures. Data through March 31, 2026. Deals among global large-cap biopharma and Chinese domiciled biopharma.

Biopharma M&A remained active in Q1 2026 following a strong 2025 rebound


NUMBER OF BIOPHARMA M&A DEALS AND UPFRONT CASH AND EQUITY^{1,2}



MEDIAN M&A UPFRONT CASH AND EQUITY^{1,2}



COUNT OF M&A DEALS BY ACQUIRED COMPANY TYPE^{1,2}




Biopharma M&A totaled \$40.9 billion in committed upfront value across 32 deals in Q1 2026, down slightly from the elevated pace seen in Q4 2025 but still consistent with continued strategic activity. Median upfront cash and equity reached \$1.4 billion in Q1 2026, indicating that buyers remain willing to pay for high-quality assets even as broader valuation discipline persists.

Private companies continued to account for a significant share of target volume, while strategic buyers remained focused on pipeline replenishment and selective late-stage acquisitions. Notable deals include Merck's acquisition of Terns Pharmaceuticals for \$6.7 billion, and Eli Lilly's acquisition of Centessa Pharmaceuticals for \$7.8 billion (\$6.3 billion upfront).


Note: ¹Financials based on disclosed figures. Data through March 31, 2026. ²Biopharma M&A with any buyer type, acquisition options, and reverse mergers.

Biopharma M&A buyers continued to focus on later-stage and approved companies

SHARE OF BIOPHARMA M&A BY TARGET COMPANY STAGE AT ACQUISITION^{1,2}



MEDIAN M&A UPFRONT CASH AND EQUITY BY TARGET COMPANY STAGE, 2021 TO Q1 2026
LARGE-CAP (\$50B+) BIOPHARMA BUY-SIDE^{1,2}




Through Q1 2026, biopharma M&A continued to skew toward Phase II, Phase III, and approved-stage companies, reflecting continued buyer preference for more advanced and de-risked assets.

Median transaction values rise materially with asset maturity, reaching \$3.3 billion for Phase III companies and \$7.3 billion for approved-stage targets across 2021-Q1 2026, underscoring the premium placed on later-stage assets.

Note: ¹Financials based on disclosed figures. Data through March 31, 2026. ²Biopharma-to-Biopharma M&A, acquisition options, and reverse mergers.

Biopharma IPO activity improved modestly in Q1 2026

NASDAQ AND NYSE COMPLETED IPOs IN BIOPHARMA THERAPEUTICS AND PLATFORMS: TOTALS (\$B) AND COUNT^{1 2}



Biopharma IPO activity showed encouraging early momentum in Q1 2026, with six offerings on NASDAQ and NYSE raising \$1.8 billion—already surpassing the \$1.6 billion in total proceeds generated across all of 2025.

While the IPO count remains a fraction of the 99 offerings completed during the 2021 peak, the strength of Q1 proceeds suggests that when the right issuers come to market, investor demand is there to meet them. That said, the window remains open primarily to a limited set of later-stage, well-positioned companies, leaving IPOs a selective financing path relative to licensing and M&A—and reinforcing the notion that public market access in biopharma continues to favor quality and readiness over volume.

Note: ¹Financials based on disclosed figures. Data through March 31, 2026. ²Includes only NASDAQ and NYSE IPOs over \$15 million. Excludes Kenvue, Inc. (Q2 2023, \$4.4B) and other OTC focused companies. IPOs by completion date.

Chase, J.P. Morgan, JPMorgan, JPMorgan Chase, and Story by J.P. Morgan are marketing names for certain businesses of JPMorgan Chase & Co. and its affiliates and subsidiaries worldwide (collectively, "JPMC", "We", "Our" or "Us", as the context may require). The information in this content (website, article, event invitation or other form) does not represent an offer or commitment to provide any product or service. The views, opinions, analyses, estimates and strategies, as the case may be ("views"), expressed in this content are those of the respective authors and speakers named in those pieces, and/or the JPMC departments that publish the content and may differ from those of JPMorgan Chase Commercial Banking and/or other JPMC employees and affiliates. These views are as of a certain date and often based on current market conditions, and are subject to change without notice. Any examples used are generic, hypothetical and for illustration purposes only. Any prices/quotes/statistics included have been obtained from sources deemed to be reliable, but we do not guarantee their accuracy or completeness. To the extent indices have been used in this content, please note that it is not possible to invest directly in an index. This is not a product of the Research Department of J.P. Morgan Securities LLC. This information in no way constitutes research and should not be treated as such. Any information related to cybersecurity provided is intended to help clients protect themselves from cyber fraud, not to provide a comprehensive list of all types of cyber fraud activities nor to identify all types of cybersecurity best practices.

Copying, re-publishing, or using this material or any of its contents for any other purpose is strictly prohibited without prior written consent from JPMorgan. In preparing this material, we have relied upon and assumed, without independent verification, the accuracy and completeness of all information that was acquired from public sources. Any mentions of third-party trademarks, brand names, products and services are for referential purposes only and any mention thereof is not meant to imply any sponsorship, endorsement, or affiliation unless otherwise noted. Notwithstanding anything to the contrary, the statements in this material are not intended to be legally binding. Any products, services, terms or other matters described herein (other than in respect of confidentiality) are subject to, and superseded by, the terms of separate legally binding documentation and/or are subject to change without notice.

The information in this content is not advice on legal, tax, investment, accounting, regulatory, technology or other matters. You should always consult your own financial, legal, tax, accounting or similar advisors before making any financial or investment decisions, or entering into any agreement for JPMC products or services. In no event shall JPMC or any of its directors, officers, employees or agents be liable for any use of, for any decision made or action taken in reliance upon, or for any inaccuracies or errors in or omissions from, the information in this content. We are not acting as your or any client's agent, fiduciary or advisor, including, without limitation, as a Municipal Advisor under the Securities and Exchange Act of 1934. JPMC assumes no responsibility or liability whatsoever to you or any client with respect to such matters, and nothing herein shall amend or override the terms and conditions in the agreement(s) between JPMC and any client or other person.

The information in this content does not include all applicable terms or issues, and is not intended as an offer or solicitation for the purchase or sale of any product or service. Our products and services are subject to applicable laws and regulations, as well as our service terms and policies. Not all products and services are available in all geographic areas or to all customers. In addition, eligibility for particular products and services will be determined by JPMC, including satisfaction of applicable legal, tax, risk, credit and other due diligence, and JPMC's "know your customer", anti-money laundering, anti-terrorism and other policies and procedures. Credit is subject to approval. Rates and programs are subject to change. Certain restrictions apply.

Products and services may be provided by banking affiliates, securities affiliates or other JPMC affiliates or entities. In particular, securities brokerage services other than those that can be provided by banking affiliates will be provided by appropriate registered broker/dealer affiliates, including J.P. Morgan Securities LLC and J.P. Morgan Institutional Investments Inc. Any securities provided or otherwise administered by such brokerage services are not deposits or other obligations of, and are not guaranteed by, any banking affiliate and are not insured by the Federal Deposit Insurance Corporation. Certain financial products and services are required by law to be provided only by licensed representatives and affiliates. Inquiries regarding such products and services will be referred to a licensed representative or a licensed affiliate. The information in this content is not an offer to sell, or solicit an offer to purchase, any securities by anyone in any jurisdiction in which such offer or solicitation is not authorized, or in which JPMC or the person making such an offer is not qualified to do so, or to anyone to whom it is unlawful to make such an offer or solicitation, or to anyone in any jurisdiction outside of the United States. Nothing in this content constitutes any commitment by JPMC to underwrite, subscribe for or place any securities, or to extend or arrange credit, or to provide any other product or service. JPMC contact persons may be employees or officers of any JPMC subsidiary or affiliate.

Any information requested on this invitation, page or other relevant registration form will be processed for the purposes of preparation and administration of this event. Providing the requested information will also assist us in ensuring that the event is properly tailored to meet the requirements of the attendees. By providing the information requested, you are consenting to your data being processed by employees and agents of JPMC as well as potential co-organizers for these purposes. You expressly consent to our use of your information in the manner described herein and in our privacy policy (www.jpmorgan.com/privacy).

Please note that any JPMC-hosted event or webinar that you register to attend may be recorded, and videos, photographs and other recordings may be taken, where you may be captured participating in the event. By providing the information requested on the registration form, you consent to the publication of such photographs, videos, recordings and/or likenesses (whether edited, adapted, modified or copied), and their use by us and those that we authorize, without prior notice or compensation, in any way which we may see fit now or in the future, including but not limited to, marketing and advertising. Further, you release JPMC and its employees and agents from all claims of every kind on account of such use. You also acknowledge and agree that the replay links, if any, will be shared with JPMC clients and prospects who were invited but did not register/attend, and also potentially to other third parties if the topics are relevant to them. If you do not agree with any statements in this paragraph, please make a member of our staff aware on the day of the event.

The statements made in this content or during this event, or provided in materials as part of this event, are proprietary to JPMC and are not intended to be legally binding. Any products and services described during these events are offered by JPMC subject to applicable laws and regulations and service terms.

We will provide reasonable accessibility accommodations brought to our attention.

Changes to Interbank Offered Rates (IBORs) and other benchmark rates: Certain interest rate benchmarks are, or may in the future become, subject to ongoing international, national and other regulatory guidance, reform and proposals for reform. For more information, please consult: <https://www.jpmorgan.com/IBOR>.

© 2026 JPMorgan Chase & Co. All rights reserved. JPMorgan Chase Bank, N.A. Member FDIC. JPMorgan Chase Bank, N.A., organized under the laws of the U.S.A. with limited liability. Deposits held in non-U.S. branches, are not FDIC insured.